Developing transformative medicines for neurological and mental health disorders
CNS drug discovery. CNS drug discovery. CNS drug discovery.
inspired by nature. powered by AI.
Promoting neuroplasticity.
Our lead R&D program focuses on activating the TrkB receptor pathway, which promotes neuronal survival and synaptic plasticity. Our lead candidate OT-003 and fast follower OT-1xx series have generated compelling data in a variety of CNS disorders with significant unmet need.
Pushing for a better tomorrow.
57+ Mn
... with an expected growth to over 150 Mn by 2050. This example of growing patient populations in CNS disorders shows the urgent need for new treatments addressing neurological and neuropsychiatric diseases.
24+ Mn
...with one-third being treatment resistant.
~80m
...for which there is no cure.
c65%
...do not fully recover by using antidepressant medication
Our lead asset OT-003 shows compelling efficacy across neurological disease models and we are planning our regulatory submission for Phase 1 at the end of Q3 2025. In addition, we created a pipeline of next-generation TrkB activators. These maintain OT-003's comelling pharmacology and possess a range of PK properties, enabling progression in distinct neurological disorders
We send our newsletter regularly, sharing news and trends around Pangea and our research space.
